Q3 FY23 Earnings Presentation
Diabetes
Solid commercial execution; continued strong MiniMed™ 780G and CGM performance internationally
Grew 3% driven by high-teens international growth offset by U.S. declines
MiniMed™ 780G now launched in >90 countries, with strong adoption and continued
geography expansion driving mid-teens International pump growth, doubling our
installed base Y/Y. High satisfaction scores for product experience:
•
-
94% of users satisfied with impact on quality of life²
93% users satisfied with impact on mealtimes²
ADAPT 12-month data to be presented at ATTD. Initial 6-month results demonstrated
27.6% absolute increase in Time in Range, reinforcing superiority of AID systems over
MDI + CGM.
CGM growth benefitting from strong 780G attach rate for Guardian TM 4 sensor in OUS
markets, which grew substantially faster
Extended infusion set (up to 7-day wear) now in 19 markets; strong adoption and
highest product satisfaction; U.S. reimbursement secured for 91% of direct installed
base through DME with additional access through pharmacy
Completed 100% of the warning letter commitments; ready for FDA reinspection and
remain in active FDA review for the 780G system with the Guardian™ 4 sensor
Advanced our portfolio with recent FDA submission of next-generation standalone
sensor, Simplera TM, following our CE Mark submission in Q1 FY23
'00
48%
Non-U.S.
Developed
MiniMed™
780G system1
14% •.
Emerging
Markets
$570M
-2.4% Y/Y Rep
+3.3% Y/Y Org
Guardian™ 4
sensor¹
1)
The MiniMed™ 780G & Guardian TM 4 Sensor, and Simplera TM Sensor, are not available in the U.S.
2)
Medtronic data on file: MiniMed TM 780G data uploaded voluntarily by 4,120 users in EMEA to CareLink TM Personal, from 27 August 2020 to 3 March 2021
13 Q3 FY23 Earnings Presentation | February 21, 2023
Extended
infusion set
InPen™
system
Simplera
sensor¹
TM
Medtronic
38%
U.S.View entire presentation